Seattle Genetics Starts Pivotal Trial

Xconomy Seattle — 

Seattle Genetics, the Bothell, WA-based maker of cancer drugs, said today it has started a final-stage clinical trial of SGN-35 in patients with relapsed forms of Hodgkin’s disease. The drug is an “empowered antibody” that combines the tumor-targeting ability of an antibody with a toxin to give it more kick. It will be studied in 100 patients who get a dose every three weeks, with a primary goal of showing tumor shrinkage.